MedTrace Logo

Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia

NCT02215629 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2017-01-27

No results posted yet for this study

Summary

The main purpose of this study is to test the safety and efficacy of VS-4718 in two types of leukemia patients and to find the right dose of VS-4718 for future clinical trials.

Other purposes of this study include:

* Testing for study drug VS-4718 levels in blood over time and what happens to the study drug in patients.
* To find out if there are certain biomarkers in leukemia patients that predict if and how 4718 study drug may or may not work.

Conditions

Interventions

DRUG

VS-4718

Sponsors & Collaborators

  • Verastem, Inc.

    lead INDUSTRY

Principal Investigators

  • Hagop Youssoufian, MD · Verastem, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Primary Completion
2016-09-30
Completion
2016-11-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02215629 on ClinicalTrials.gov